Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Mifepristone (HB2783)
Description:Potent glucocorticoid and progesterone receptor antagonist. Also used for gene editing as a mifepristone inducible Cas9 and Cpf1 CRISPR effector.
Purity:>99%
-
Tamoxifen (HB0601)
Description:Estrogen receptor antagonist/ partial agonist. May be used in genome engineering (e.g. CreER/ CRISPR-Cas9).
Purity:>99%
-
Tamoxifen Citrate (HB0602)
Description:Estrogen receptor antagonist/ partial agonist. May be used in genome engineering (e.g. CreER/ CRISPR-Cas9). Citrate salt.
Purity:>98%
